Development of a model-based dose-individualisation approach with an application to routine clinical data
- At: 2017 FIP Congress in Seoul (South Korea)
- Type: Presentation
- By: GUK, Jinju (Yonsei University College of Medicine, Seoul, Korea, Republic Of)
- Co-author(s): Jinju Guk
With the development of new effective antiepileptic agents, the use of phenytoin has kept decreasing. Large inter-individual variability and narrow therapeutic range in drug concentration is another reason for decrease in phenytoin use. However, phenytoin is still an essential agent for second-line treatment of status epilepticus when patients do.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.